Antares Pharma, Inc. has reported positive results from a multi-centre phase II clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous ...

Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.

EWING, N.J., May 16, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate ...

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...

Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into ...

Antares Pharma, Inc. has announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous ...